-
Dr. Lugui Qiu: Progress Flourishes with a Precision-Based Lymphoma Diagnosis and Treatment System
Lymphoma is a common malignant disease of the lymphatic system that poses a significant threat to public health. China faces a rapidly increasing burden of lymphatic tumors. The GBD 2019 study shows that China accounts for 10.8% of the world’s new cases of Hodgkin lymphoma and 9.8% of the deaths, as well as 20.1% of…
-
World Leukemia Day: Building a Health Defense, Lighting the Flame of Life
September 4 marks “World Leukemia Day,” an initiative launched by the Acute Leukemia Advocates Network, CLL Advocates Network, CML Advocates Network, and Leukaemia Care. The day is dedicated to raising global awareness about leukemia, promoting efforts in prevention, diagnosis, treatment, and recovery. Leukemia, often called “blood cancer,” is a complex disease with high treatment costs…
-
Latest Update on CheckMate 274: Adjuvant Nivolumab in High-Risk MIUC
Published in the Journal of Clinical Oncology, January 2025The CheckMate 274 phase III trial provides expanded efficacy data on adjuvant nivolumab in high-risk muscle-invasive urothelial carcinoma (MIUC) following radical resection.…
-
Dr. Jin Gu: Significant Benefits of Combined Pelvic Organ Resection for High-Risk Locally Advanced Rectal Cancer | Guangzhou Colorectal Cancer Summit
From August 5th to 10th, 2024, the Guangzhou Colorectal Cancer Summit Forum and the 22nd Guangdong Provincial Colorectal Cancer Academic Conference were held in Guangzhou. During the event, Dr. Jin Gu from Peking University Shougang Hospital shared important insights and conclusions from his center’s experience with combined pelvic organ resection surgery for refractory rectal cancer.…
-
CSCO 2024丨Dr. Jiong Wu: INAVO120 Accelerates the Approval of New PI3Ki Inavolisib by CDE, Gene Testing Propels the Era of Precision Targeted Therapy
Hormone receptor-positive (HR+) breast cancer is the most common subtype of breast cancer, with approximately 40% of these patients harboring a PI3KCA mutation. This mutation is a primary cause of resistance to endocrine therapy and CDK4/6 inhibitors, leading to poorer prognosis for affected patients. At the 2024 CSCO Annual Meeting, Dr. Jiong Wu from Fudan…
-
Breaking News: Updated EV-302 Trial Analysis at ASCO GU 2025
Presented at the ASCO GU Annual Symposium (February 13–15, 2025), San FranciscoThe EV-302 (KEYNOTE-A39) trial provided new insights into enfortumab vedotin plus pembrolizumab (EV+P) versus platinum-based chemotherapy in previously untreated…
-
Throwback to the SACI-IO HR+ Trial in Metastatic Breast Cancer
Presented at the 2024 ASCO Annual Meeting on June 5, the SACI-IO HR+ trial investigated sacituzumab govitecan (SG) with or without pembrolizumab in patients with hormone receptor-positive/HER2-negative metastatic breast cancer…
-
New Insights from the NuTide:121 Trial in Advanced Biliary Tract Cancer
Published on February 18, 2025, in the Journal of Hepatology, the NuTide:121 study investigated NUC-1031/cisplatin as a first-line treatment for advanced biliary tract cancer (aBTC) compared to the gemcitabine/cisplatin standard…
Connecting Medical Expertise through Media